Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 7;37(1):121-137.e6.
doi: 10.1016/j.cmet.2024.09.012. Epub 2024 Oct 21.

Overnutrition causes insulin resistance and metabolic disorder through increased sympathetic nervous system activity

Affiliations

Overnutrition causes insulin resistance and metabolic disorder through increased sympathetic nervous system activity

Kenichi Sakamoto et al. Cell Metab. .

Abstract

The mechanisms underlying obesity-induced insulin resistance remain incompletely understood, as impaired cellular insulin signaling, traditionally considered the primary driver of insulin resistance, does not always accompany impaired insulin action. Overnutrition rapidly increases plasma norepinephrine (NE), suggesting overactivation of the sympathetic nervous system (SNS). However, the role of the SNS in obesity is controversial, as both increased and decreased SNS activity (SNA) have been reported. Here, we show that reducing catecholamine (CA) release from the SNS protects against overnutrition-induced insulin resistance as well as hyperglucagonemia, adipose tissue dysfunction, and fatty liver disease, as we demonstrate utilizing a mouse model of inducible and peripherally restricted deletion of tyrosine hydroxylase (th; THΔper). A key mechanism through which heightened SNA induces insulin resistance is by triggering adipose tissue lipolysis. Increased SNA emerges as a critical driver in the pathogenesis of overnutrition-induced insulin resistance and metabolic disease independent of cellular insulin signaling.

Keywords: adipose tissue dysfunction; adipose tissue lipolysis; diabetes; insulin resistance; liver steatosis; metabolic disease; metabolic inflammation; norepinephrine; obesity; sympathetic nervous system.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests C.B. received research support from Pfizer and consulted for Boehringer and Novo Nordisk, all of which were unrelated to the work described in this manuscript. G.M. is part of the editorial team at Elsevier.

References

    1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, and Dietz WH (1999). The disease burden associated with overweight and obesity. Jama 282, 1523–1529. 10.1001/jama.282.16.1523. - DOI - PubMed
    1. Choe SS, Huh JY, Hwang IJ, Kim JI, and Kim JB (2016). Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Front Endocrinol (Lausanne) 7, 30. 10.3389/fendo.2016.00030. - DOI - PMC - PubMed
    1. Boden G (2006). Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 6, 177–181. 10.1007/s11892-006-0031-x. - DOI - PubMed
    1. Eissing L, Scherer T, Todter K, Knippschild U, Greve JW, Buurman WA, Pinnschmidt HO, Rensen SS, Wolf AM, Bartelt A, et al. (2013). De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat Commun 4, 1528. 10.1038/ncomms2537. - DOI - PMC - PubMed
    1. Song Z, Xiaoli AM, and Yang F (2018). Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues. Nutrients 10. 10.3390/nu10101383. - DOI - PMC - PubMed

LinkOut - more resources